DrugPatentWatch Database Preview
OSENI Drug Profile
Which patents cover Oseni, and when can generic versions of Oseni launch?
Oseni is a drug marketed by Takeda Pharms Usa and is included in one NDA. There are eight patents protecting this drug.
This drug has one hundred and ninety patent family members in forty-three countries.
The generic ingredient in OSENI is alogliptin benzoate; pioglitazone hydrochloride. There are ten drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the alogliptin benzoate; pioglitazone hydrochloride profile page.
Summary for OSENI
International Patents: | 190 |
US Patents: | 8 |
Applicants: | 1 |
NDAs: | 1 |
Suppliers / Packagers: | 2 |
Bulk Api Vendors: | 1 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for OSENI |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for OSENI |
DailyMed Link: | OSENI at DailyMed |

Generic Entry Opportunity Date for OSENI
Generic Entry Date for OSENI*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for OSENI
US Patents and Regulatory Information for OSENI
Expired US Patents for OSENI
International Patents for OSENI
Country | Document Number | Estimated Expiration |
---|---|---|
Spain | 2288807 | ➤ Try a Free Trial |
Germany | 122009000064 | ➤ Try a Free Trial |
Germany | 602004015067 | ➤ Try a Free Trial |
Malaysia | 146290 | ➤ Try a Free Trial |
Tunisia | 2009000317 | ➤ Try a Free Trial |
Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for OSENI
Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|
14/012 | Ireland | ➤ Try a Free Trial | PRODUCT NAME: ALOGLIPTIN AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTRATION NO/DATE: EU/1/13/844/001-027 20130919 |
0861666/01 | Switzerland | ➤ Try a Free Trial | FORMER REPRESENTATIVE: BOHEST AG, CH |
C/GB07/009 | United Kingdom | ➤ Try a Free Trial | SPC/GB07/009: 20070126 |
C/GB10/011 | United Kingdom | ➤ Try a Free Trial | PRODUCT NAME: THE COMBINATION OF PIOGLITAZONE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, ESPECIALLY THE HYDROCHLORIDE SALT, AND GLIMEPIRIDE.; REGISTERED: UK EU/1/06/366/001 20070108; UK EU/1/06/366/002 20070108; UK EU/1/06/366/003 20070108; UK EU/1/06/366/004 20070108; UK EU/1/06/366/005 20070108; UK EU/1/06/366/006 20070108; UK EU/1/06/366/019 20070108; UK EU/1/06/366/020 20070108; UK EU/1/06/366/021 20070108; UK EU/1/06/366/022 20070108; UK EU/1/06/366/013 20070108; UK EU/1/06/366/014 20070108; UK EU/1/06/366/015 20070108; UK EU/1/06/366/016 20070108; UK EU/1/06/366/017 20070108; UK EU/1/06/366/018 20070108; UK EU/1/06/366/007 20070108; UK EU/1/06/366/008 20070108; UK EU |
2007 00001 | Denmark | ➤ Try a Free Trial | |
Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |